Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,199 | 224 | 948 |
| Samples | 589 | 139 | 438 |
| Peptides | 500 | 94 | 408 |
Function
ARID5B · AT-rich interaction domain 5B
This gene encodes a member of the AT-rich interaction domain (ARID) family of DNA binding proteins. The encoded protein forms a histone H3K9Me2 demethylase complex with PHD finger protein 2 and regulates the transcription of target genes involved in adipogenesis and liver development. This gene also plays a role in cell growth and differentiation of B-lymphocyte progenitors, and single nucleotide polymorphisms in this gene are associated with acute lymphoblastic leukemia. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Sep 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000279873 | Q14865 | 643 | 481 |
| ENST00000309334 | Q14865-2 | 452 | 355 |
| ENST00000644638 | A0A2R8Y5F2* | 99 | 89 |
| ENST00000681100 | A0A7P0TAD2* | 5 | 5 |
Gene Properties
Recurrent Mutations
All 481 amino-acid changes on canonical ENST00000279873 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ARID5B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ARID5B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 30/612 5% |
| Hodgkins Lymphoma | 3/16 19% | 5/122 4% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Melanoma | 16/210 8% | 66/1899 3% |
| Colorectal Carcinoma | 16/143 11% | 75/3239 2% |
| Gastric Carcinoma | 6/74 8% | 32/1809 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 14/810 2% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 14/1390 1% |
| Other Solid Cancers | 0/94 0% | 22/1515 1% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Ovarian Carcinoma | 8/109 7% | 6/998 1% |
| Neuroendocrine Tumour | 5/154 3% | 4/577 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Biliary Tract Carcinoma | 1/54 2% | 9/950 1% |
| Head and Neck Carcinoma | 1/85 1% | 15/1574 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Hepatocellular Carcinoma | 2/46 4% | 18/2210 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Breast Carcinoma | 10/144 7% | 20/3264 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 4/752 1% |
| Pancreatic Carcinoma | 3/89 3% | 10/1611 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Glioma | 1/52 2% | 14/2127 1% |
| Kidney Carcinoma | 0/85 0% | 13/1862 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 15/2550 1% |
Mutation Distribution
Where ARID5B is mutated · all tissues, split by cell line vs tissue
How many mutations in ARID5B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,199 mutations in ARID5B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|